[go: up one dir, main page]

US20020137937A1 - Process for preparing [S- (R*, S*) ] -beta- [ [ [1- [1-oxo-3- (4-piperidinyl) propyl] -3-piperidinyl] carbonyl]amino] -3-pyridinepropanoic acid and derivatives - Google Patents

Process for preparing [S- (R*, S*) ] -beta- [ [ [1- [1-oxo-3- (4-piperidinyl) propyl] -3-piperidinyl] carbonyl]amino] -3-pyridinepropanoic acid and derivatives Download PDF

Info

Publication number
US20020137937A1
US20020137937A1 US10/081,289 US8128902A US2002137937A1 US 20020137937 A1 US20020137937 A1 US 20020137937A1 US 8128902 A US8128902 A US 8128902A US 2002137937 A1 US2002137937 A1 US 2002137937A1
Authority
US
United States
Prior art keywords
formula
compound
salt
reacting
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/081,289
Inventor
Judith Cohen
Michael Justus
Cynthia Maryanoff
Armin Rossler
Fridtjof Schroder
Kirk Sorgi
Frank Villani
Christian Weh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/081,289 priority Critical patent/US20020137937A1/en
Publication of US20020137937A1 publication Critical patent/US20020137937A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters

Definitions

  • the invention relates to a process of preparing [S-(R*,S*)]- ⁇ -[[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridinepropanoic acid derivatives represented by the formula
  • R 1 and R 2 are independently selected/from hydrogen, lower alkyl and halogen.
  • Compounds of formula I are antagonists of the platelet fibrinogen receptor (GP 11b/111a antagonist).
  • the compounds of formula I are useful for the treatment of thrombotic disorders such as restenosis post-angioplasty, unstable/stable angina and myocardial infarction.
  • a known method of the preparation of a compound of formula I is disclosed in WO 97/41102 involving coupling of enantiomerically enriched methyl (S)-3-amino-3-pyridylpropanoate with N-(t-butoxycarbonyl)-(R)-nipecotic acid followed by removal of the N-t-butoxycarbonyl protecting group under acidic conditions and coupling with 3-(N-t-butoxycarbonyl-4-piperidyl)propionic acid.
  • the crude ester product is then hydrolyzed using aqueous LiOH and the N-t-butoxycarbonyl amino protecting group is removed under acidic conditions with trifluoroacetic acid (“TFA”).
  • TFA trifluoroacetic acid
  • the current invention relates to a more efficient process of preparing compounds of formula I.
  • the invention relates to a process of preparing a compound of formula I
  • R 1 and R 2 are independently selected from the group consisting of hydrogen, lower alkyl and halogen, comprising coupling 3-(N-benzyloxycarbonyl-4-piperidyl)propionic acid calcium salt of formula II as described herein, with (R)-( ⁇ )lower alkyl nipecotate-(+)-tartrate of formula III, as described herein to form a compound of formula IV
  • R 1 and R 2 are as described above and R 4 is lower alkyl or aralkyl
  • the claimed invention relates to a process of preparing the compound of formula VI, preferably methyl(S)-3-amino-3-(3-pyridyl) propanoate, an intermediate in the synthesis of a compound of formula I, by classical resolution of racemic methyl 3-amino-3-(3-pyridyl) propanoate using (+)-tartaric acid.
  • This new process led to a more cost effective and volume efficient synthesis of enantiomerically pure methyl (S)-3-amino-3-(3-pyridyl)propanoate in good yield and high purity.
  • Another aspect of the claimed invention relates to a process for preparing the intermediate (R)-( ⁇ )lower alkyl nipecotate (+) tartrate salt which involves resolving racemic ( ⁇ )lower alkyl nipecotate using (+) tartaric acid in an isopropyl alcohol and water mixture.
  • a further aspect of the claimed invention relates to the purification of the compound of formula I by dissolving the free base of formula I in an organic solvent and adjusting the pH in the range of from about 4 to about 12 in the presence of an organic amine base to precipitate the purified compound of formula I.
  • Costanzo, et al., in WO97/41102, Nov. 6, 1997 disclose the compound of formula Ia as a free base.
  • a further aspect of the claimed invention relates to a novel crystalline form of the compound of formula Ia.
  • alkyl whether used alone or as part of a substituent group, include straight and branched chains.
  • alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and the like.
  • lower when used with alkyl means a carbon chain composition of 1-4 carbon atoms.
  • aralkyl shall mean any lower alkyl group substituted with an aryl group such as phenyl, naphthyl and the like.
  • halogen means fluorine, chlorine, iodine or bromine.
  • hydrolysis catalyst shall mean a catalyst of rhodium (Rh), palladium (Pd) or platinum (Pt) which is adsorbed on a solid support such as Rh on carbon, Pd on carbon, Pd(OH) 2 on carbon or Pt on carbon or unsupported such as PtO 2 .
  • the process relates to a process of preparing a compound of formula I wherein R 1 and R 2 are hydrogen.
  • the invention relates to a process of preparing a compound of formula I as more fully described in the schemes below.
  • 3-(4-pyridine)acrylic acid a known compound, is reduced to 3-(4-piperidyl)propionic acid by catalytic hydrogenation in a basic solvent such as inorganic bases, for example, alcoholates, hydroxide, hydrogen carbonate, carbonate of alkali or earth alkali metals or ammonia; or organic bases, for example, primary, secondary, or tertiary alkylamines, in aqueous or alcoholic solution, preferably aqueous ammonia, in the presence of a rhodium catalyst, preferably rhodium on Al 2 O 3 at a temperature of from about room temperature to about 95°, preferably 80-95° C. at a pH in the range of about 7-13, preferably about 7-8.
  • a basic solvent such as inorganic bases, for example, alcoholates, hydroxide, hydrogen carbonate, carbonate of alkali or earth alkali metals or ammonia; or organic bases, for example, primary, secondary, or tertiary alkyl
  • 3-(4-Piperidyl)propionic acid is reacted with a reagent capable of placing a benzyloxy carbonyl protecting group on an amine such as N-(benzyloxy carbonyloxy) succinimide (Cb z OSu), N-benzyloxy carbonyloxy-5-norbornene-2,3-dicarboximide, or benzyl chloroformate, preferably benzyl chloroformate in a basic calcium salt, such as aqueous Ca(OH) 2 or calcium carbonate, preferably Ca (OH) 2 , at a temperature in the range of from 0 to room temperature, preferably 0-10° C. and preferably at a pH in the range of about 8-14, preferably about 11-14, to form the 3-(N-benzyloxycarbonyl-4-piperidyl) propionic acid calcium salt of formula II.
  • a reagent capable of placing a benzyloxy carbonyl protecting group on an amine such as N-
  • a coupling reagent such as 1,3-dicylcohexyl carbodiimide (DCC), O-benzotriazole-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU), or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, preferably DCC, in the presence of 0 to 1 equivalents, preferably 0.1 equivalents, of an additive such as 1-hydroxybenzotriazole hydrate (HOBT) or 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (HOOBT), preferably HOBT, in a solvent mixture of an organic solvent and water, such as, ethyl acetate/water or tetrahydrofuran/water or a polar organic solvent, such as dimethylformamide or 1-methyl-2-
  • a coupling reagent such as 1,3-dicylco
  • the compound of formula IV is hydrolyzed in an inorganic base such as lithium hydroxide, sodium hydroxide, preferably lithium hydroxide, in an organic solvent such as THF or dioxane, at a temperature in the range of from about 0 to about 50° C., preferably 5-25° C. at a pH preferably in the range of about 10 to about 13, to form the compound of formula V.
  • an inorganic base such as lithium hydroxide, sodium hydroxide, preferably lithium hydroxide
  • organic solvent such as THF or dioxane
  • the compound of formula V is reacted with a carboxylic acid salt of the compound of formula VI, preferably the tartrate salt, in the presence of a coupling reagent such as 1,3-dicyclohexylcarbodiimide (DCC), 0-benzotriazole-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU), or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, preferably DCC, in the presence of 0 to 1 equivalents, preferably 0.1 equivalents of an additive such as 1-hydroxybenzotriazole hydrate (HOBT) or 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (HOOBT), preferably HOBT, preferably DCC and HOBT, in the presence of a calcium salt such as calcium hydroxide, calcium carbonate, and the like, preferably calcium hydrox
  • the compound of formula V is reacted with a compound of formula VI or an inorganic salt thereof, preferably HCl salt, a known compound or compound prepared by known methods WO 97/41102, in the presence of a coupling reagent such as 1,3-dicyclohexylcarbodiimide (DCC), 0-benzotriazole-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU), or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, preferably DCC, in the presence of 0 to 1 equivalents, preferably 0.1 equivalents of an additive such as 1-hydroxybenzotriazole hydrate (HOBT) or 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (HOOBT), preferably HOBT, preferably DCC and HOBT, to form the corresponding compound of
  • the compound of formula VII is reacted in an organic solvent, such as THF, dioxane, or DMF, preferably THF, in the presence of an inorganic base such as sodium hydroxide, or lithium hydroxide, preferably lithium hydroxide, at a temperature in the range of from 0-40° C., preferably 10-15° C., preferably at a pH in the range of about 8-11.
  • an inorganic acid such as sulfuric, hydrochloric, and the like, preferably to a pH of about 3-5, to yield the corresponding compound of formula VIII.
  • the acidification results in the precipitation of N,N′-bis(2,2,2-trichloro-1-hydroxyethyl)urea (DCU), which is preferably removed prior to the next step.
  • DCU N,N′-bis(2,2,2-trichloro-1-hydroxyethyl)urea
  • the compound of formula VIII is converted to the corresponding compound of formula I via catalytic hydrogenation using a hydrogenation catalyst, preferably a palladium catalyst such as Pd/C, in a polar solvent such as an alcohol, preferably methanol or ethanol, at a temperature of from 30-50° C.
  • a hydrogenation catalyst preferably a palladium catalyst such as Pd/C
  • a polar solvent such as an alcohol, preferably methanol or ethanol
  • the compound of formula I is purified by heating the compound of formula I in an organic solvent such as ethylacetate, methyl t-butyl ether, methanol, ethanol, n-butanol and the like, preferably n-butanol, to a temperature up to 85°, preferably 75-85° C. The solution is then cooled to a temperature in the range of about 20-30° C.
  • An amine organic base such as triethylamine, cyclohexylamine, t-butylamine and the like, preferably t-butylamine, is added in an amount sufficient to result in a pH in the range of about 4-12, preferably about 7-11, most preferably 7.5.
  • a compound of formula IX a known compound or compound prepared by known methods, J. Am. Chem Soc 1957, Vol. 79, p. 159, is converted to a corresponding compound of formula X by dissolution in an organic solvent such as, methanol, isopropanol, toluene and mixtures thereof, with at least one equivalent of gaseous NH 3 at a temperature in the range of from 40-100° C., preferably 60-65° C. in the presence of a carboxylic acid such as acetic acid or formic acid.
  • an organic solvent such as, methanol, isopropanol, toluene and mixtures thereof
  • the compound of formula X is reduced to the corresponding compound of formula XI, preferably by reacting with borohydride reagents such as sodium borohydride, in an organic solvent such as THF, in the presence of an organic acid such as propionic acid, benzoic acid, acetic acid, or trifluoroacetic acid (TFA), preferably acetic acid or TFA, at a temperature in the range of ⁇ 5 to 10° C. at a pH in the range of about 1-6.
  • borohydride reagents such as sodium borohydride
  • organic solvent such as THF
  • an organic acid such as propionic acid, benzoic acid, acetic acid, or trifluoroacetic acid (TFA), preferably acetic acid or TFA
  • the reaction is quenched with an alcohol, preferably methanol and a strong acid such as hydrochloric or sulfuric, preferably hydrochloric, to afford a compound of formula XI as a salt.
  • the amine is freed by reacting the salt of the compound of formula XI with a tertiary amine such as triethylamine, DIPEA, or NMM, preferably triethylamine, in an organic solvent such as acetonitrile, THF, or dioxane, preferably acetonitrile.
  • a tertiary amine salt is separated by conventional methods such as filtration or extraction, preferably filtration, to afford the compound of formula XI as the free amino ester.
  • the compound of formula XI is heated in the presence of (+)-tartaric acid, preferably 0.25 equivalents of (+) tartaric acid, to a temperature resulting in the formation of a solution in a polar solvent, such as alcohol, for example, methanol or ethanol or an alcohol water mixture, such as methyl alcohol/water or ethyl alcohol/water, preferably ethyl alcohol/water mixture at a ratio of 90:10 to 100% ethanol, preferably at a ratio of 97:3 and cooled to a temperature in the range of 25-30° C. to form the corresponding salt of formula XII.
  • a polar solvent such as alcohol, for example, methanol or ethanol or an alcohol water mixture, such as methyl alcohol/water or ethyl alcohol/water, preferably ethyl alcohol/water mixture at a ratio of 90:10 to 100% ethanol, preferably at a ratio of 97:3 and cooled to a temperature in the range of 25-30° C. to form the corresponding
  • the tartrate salt of formula XII is converted to the corresponding compound of formula VI or salt thereof, by known methods.
  • the salt of formula XII is reacted with at least two equivalents, preferably between 8 and 11 equivalents, of gaseous HCl, in a polar solvent, such as methanol, ethanol, isopropyl alcohol, ethyl acetate or mixture thereof, at a temperature in the range of 0-50° C., preferably at about 10° C., to form the corresponding dihydrochloride salt of formula VI.
  • a polar solvent such as methanol, ethanol, isopropyl alcohol, ethyl acetate or mixture thereof, at a temperature in the range of 0-50° C., preferably at about 10° C.
  • R 4 is methyl
  • the preferred solvent is methanol.
  • the compound of formula XIII a known compound or compound prepared by known methods (Eur. J. Pharmacol., 1983, 89(3-4),217), is reacted with (+)tartaric acid, preferably one equivalent (+) tartaric acid in a mixture of isopropyl alcohol (IPA) and water, preferably at a ratio of 90:10 up to 100% IPA, more preferably at a ratio of 94:6, and heating to form a solution, preferably at a temperature in the range of from 73-77° C. then cooled to no less than 20° C., preferably 26-30° C., to form the corresponding salt of formula III.
  • (+)tartaric acid preferably one equivalent (+) tartaric acid in a mixture of isopropyl alcohol (IPA) and water
  • IPA isopropyl alcohol
  • IPA isopropyl alcohol
  • a further aspect of the present invention is a novel crystalline forms of the compound of formula Ia, characterized by its x-ray powder diffraction pattern, utilizing a Philips PW3710 based powder diffractometer using CuK ⁇ radiation and the following system conditions:
  • the novel crystal form of the compound of formula Ia appears as irregular acicular particles crystals and may be characterized essentially by its X-ray diffraction pattern: POWDER X-RAY DIFFRACTION RESULTS d Spacing Relative Angle ° 2 ⁇ ( ⁇ ) Intensity (%) 8.77 10.09 17.50 10.52 8.41 16.20 15.57 5.69 100.00 15.90 5.65 22.70 16.52 5.37 48.30 17.48 5.08 25.80 17.72 5.01 24.70 18.32 4.85 58.10 19.62 4.53 21.50 19.98 4.45 47.30 20.28 4.38 41.50 21.08 4.22 67.80 21.36 4.16 18.10 22.82 3.90 23.50 23.26 3.83 50.40 24.01 3.71 57.60 24.73 3.60 24.10 25.62 3.48 9.90 25.99 3.43 8.00 26.37 3.38 4.60 27.37 3.26 13.50 27.98 3.19 23.20 28.62 3.12 15.70 30.20 2.96 19.00
  • Acetonitrile (116 kg) was added and then the mixture was concentrated (ca. 50%) under vacuum. Additional acetonitrile (57.1 kg) was added to aid in crystallization and the reaction mixture was stirred for 1-4 hours at 15-25° C. until precipitation of the product was complete. The product was centrifuged and oven dried under vacuum at 45-55° C. to afford 19.1 kg (100%) of the title compound.
  • L-(+)-Tartaric acid (47.74 g, 318 mmol) was suspended in 265 g of isopropyl alcohol and 16.91 g of water. The mixture was heated to 60-65° C. to afford a homogeneous solution. One equivalent of ( ⁇ )-ethyl nipecotate (50 g, 318 mmol) was added while the temperature was maintained at or below 75° C. The mixture was stirred at 70-75° C. for 20-30 minutes, then cooled to 60° C. over 60 minutes.
  • the reaction mixture was warmed slowly to 20-25° C. and N,N-dichlorourethane (DCU) precipitated. After 4h, the DCU was removed by filtration and washed with 8 g of THF. The filtrate was cooled to 0-5° C. and lithium hydroxide (6.67 g, 159.0 mmol) in 60.38 g of water was added at 0-5° C. The pale yellow solution was warmed to ambient temperature. After 3 h, the solvent was removed by distillation under vacuum at or below 55° C. Ethyl acetate (45.4 g) was added and the pH was adjusted to exactly 4.0 with ca. 18.6 g of concentrated HCl. DCU precipitated and was filtered from the mixture.
  • DCU N,N-dichlorourethane
  • the first procedure (A) involved two steps for the production of enantiomerically pure methyl(s)-3-amino-3-(3-pyridyl)propanoate dihydrochloride via NaBH 4 reduction.
  • the second procedure (B) involved three steps for the production of enantiomerically pure methyl(S)-3-amino-3-(3-pyridyl)propanoate dihydrochloride via hydrogenation.
  • Glacial acetic acid (526.9 g, 8.78 mol) was added dropwise at ⁇ 5° C. to a suspension of methyl 3-amino-3-(3-pyridyl)-2-propenoate (0.45mol) and sodium borohydride (44.3 g, 1.17mol) in THF (500 g) and the resulting reaction mixture was stirred at ⁇ 5-0° C. After 5 h, methanol (600 9) was added dropwise to the solution at -5-0° C. After 0.5 hours, HCl (163 g, 4.47 mol) was bubbled through the solution and stirred at 0° C. After 8 h, the white precipitate was filtered off and dried at 40° C. to yield 101.6 g (89%) of methyl 3-Amino-3-(3-pyridyl)propanoate dihydrochloride.
  • Methyl nicotinoylacetate (88 g, 0.5 mol) was dissolved in toluene (200 g), isopropyl alcohol (200 g), and formic acid (98-100%, 1.22 g, 0.03 mol) and heated to 60-65° C. Gaseous ammonia (23 g, 1.35 mol) was bubbled through the solution for 15 minutes. The white suspension was stirred at 65° C. until a homogeneous solution formed. The solution was stirred for two hours at 65° C. and then concentrated (ca. 200 g) at 65° C. The residue was cooled to ⁇ 5° C.
  • Racemic methyl 3-amino-3-(3-pyridyl)propanoate dihydrochloride(150 g, 0.563 mol) was suspended in acetonitrile (425 g).
  • Triethylamine (125.3 g, 1.239 mol) was added dropwise while the temperature was maintained at 35° C. or less.
  • the reaction was stirred for a minimum of two hours at 20° C. then cooled to 50C. After 0.5 hours the resulting precipitate was centrifuged and washed with 50 g of acetonitrile. The acetonitrile was removed by distillation at 40-45° C.
  • the crude tartrate salt was slurried at 35-40° C. for two hours in a mixture of 150 g of ethanol and 4.6 g of water. The mixture was stirred for 0.5 hours at 25° C. The resulting precipitate was isolated and washed with 30 g of ethanol. Up to three slurries may be necessary to achieve a >98% de.
  • the precipitate was suspended in methanol (100 g) and a minimum of 10 equiv. HCl gas (51.3 g, 1.408 mol) was added. The reaction mixture was stirred at 22-28° C. until the reaction was complete by HPLC. Ethyl acetate (160 g) was added and the reaction mixture was stirred at 0-5° C.
  • the mixture was warmed to 20-25° C. and stirred for 12 hours.
  • the suspension was cooled to 0-5° C. and the precipitated DCU was filtered off and washed with 81 kg of pre-cooled ethyl acetate.
  • the solvent was distilled from the filtrate, and the residual oil was dissolved twice in 50 kg of ethyl acetate and the solvent removed.
  • the resulting oil was dissolved in 162 kg of ethyl acetate and washed three times with a solution of 6.3 kg of NaHCO 3 in 120 kg of water to remove excess HOBT.
  • the filtrate was reduced to a colorless oil under reduced pressure at 40-50° C.
  • the crude product was dissolved in 60 kg of n-butyl alcohol and concentrated to an oil, which began to bubble or foam.
  • the crude product was slurried in 756 kg of n-butyl alcohol and heated to 75-85° C. for 15-20 minutes, then cooled to 20-30° C.
  • t-Butylamine (0.7 kg) was added (pH 7.5) and the reaction was stirred.
  • the reaction mixture was cooled to 0-5° C. and stirred for an additional hour.
  • the precipitate was isolated, washed with 102 kg of MTBE, and dried under vacuum at 60-80° C. to yield 36 kg (58%) of the title compound as a white crystalline solid.
  • the reaction mixture was cooled to 0-5° C. and treated with a solution of sulfuric acid (250 g) in water (1.14 kg) to achieve a pH of 3.9-4.1.
  • the precipitated DCU was collected by filtration and washed with THF (400 g).
  • the resulting phases were separated and the organic phase washed with a saturated NaCl solution (1 kg).
  • the organic layer was distilled and the resulting oil dissolved in THF (2 kg).
  • the solvent was removed until a water content of ⁇ 2% was achieved.
  • the precipitated inorganic salts were removed.
  • the filtrate was concentrated and the resulting oil dissolved in MeOH (2kg).
  • the solution was evaporated under vacuum at 45° C.
  • the crude product was taken up in n-butyl alcohol (1.7 kg) and heated to 75-85° C. for 1-3 h, then cooled to 20-30° C. for 2-3 h. The resulting suspension was cooled to 0-5° C. and stirred for an additional 1 h. The precipitate was isolated, washed with MTBE (1.7 kg), and dried under vacuum at 60-80° C. to yield 36 kg (53%) of the title compound as a white crystalline solid.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A process for preparing a compound of formula I
Figure US20020137937A1-20020926-C00001
wherein R1 and R2 are independently selected from the group consisting of hydrogen, lower alkyl and halogen

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application claims benefit to U.S. Provisional Application No. 60/125,671, filed on Mar. 22, 1999.[0001]
    • BACKGROUND OF THE INVENTION
  • Field of the Invention [0002]
  • The invention relates to a process of preparing [S-(R*,S*)]-β-[[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridinepropanoic acid derivatives represented by the formula [0003]
    Figure US20020137937A1-20020926-C00002
  • wherein R[0004] 1 and R2 are independently selected/from hydrogen, lower alkyl and halogen.
  • The compounds of formula I and method of making and using the compounds of formula I are described in WO 97/41102, Nov. 6, 1997. [0005]
  • Compounds of formula I are antagonists of the platelet fibrinogen receptor (GP 11b/111a antagonist). Thus, the compounds of formula I are useful for the treatment of thrombotic disorders such as restenosis post-angioplasty, unstable/stable angina and myocardial infarction. [0006]
  • A known method of the preparation of a compound of formula I is disclosed in WO 97/41102 involving coupling of enantiomerically enriched methyl (S)-3-amino-3-pyridylpropanoate with N-(t-butoxycarbonyl)-(R)-nipecotic acid followed by removal of the N-t-butoxycarbonyl protecting group under acidic conditions and coupling with 3-(N-t-butoxycarbonyl-4-piperidyl)propionic acid. The crude ester product is then hydrolyzed using aqueous LiOH and the N-t-butoxycarbonyl amino protecting group is removed under acidic conditions with trifluoroacetic acid (“TFA”). The bis-TFA salt is isolated as a white amorphous solid. [0007]
  • A process for preparing N-(3-piperidinyl carbonyl)-β-alanine derivatives is disclosed in WO 95/08536. [0008]
  • The current invention relates to a more efficient process of preparing compounds of formula I. [0009]
    • BRIEF SUMMARY OF THE INVENTION
  • The invention relates to a process of preparing a compound of formula I [0010]
    Figure US20020137937A1-20020926-C00003
  • wherein R[0011] 1 and R2 are independently selected from the group consisting of hydrogen, lower alkyl and halogen, comprising coupling 3-(N-benzyloxycarbonyl-4-piperidyl)propionic acid calcium salt of formula II as described herein, with (R)-(−)lower alkyl nipecotate-(+)-tartrate of formula III, as described herein to form a compound of formula IV
    Figure US20020137937A1-20020926-C00004
  • wherein R[0012] 3 lower alkyl and Ph is phenyl, reacting the compound of formula IV to form th e compound of formula V
    Figure US20020137937A1-20020926-C00005
  • reacting the compound of formula V with a compound of formula VI [0013]
    Figure US20020137937A1-20020926-C00006
  • wherein R[0014] 1 and R2 are as described above and R4 is lower alkyl or aralkyl,
  • to form the compound of formula VII [0015]
    Figure US20020137937A1-20020926-C00007
  • wherein R[0016] 1, R2, R4 and Ph are as described above, reacting the compound of formula VII to form the compound of formula VIII
    Figure US20020137937A1-20020926-C00008
  • wherein R[0017] 1, R2, and Ph are as described above, reacting the compound of formula VIII to form the compound of formula I.
  • In another aspect, the claimed invention relates to a process of preparing the compound of formula VI, preferably methyl(S)-3-amino-3-(3-pyridyl) propanoate, an intermediate in the synthesis of a compound of formula I, by classical resolution of racemic methyl 3-amino-3-(3-pyridyl) propanoate using (+)-tartaric acid. This new process led to a more cost effective and volume efficient synthesis of enantiomerically pure methyl (S)-3-amino-3-(3-pyridyl)propanoate in good yield and high purity. [0018]
  • Another aspect of the claimed invention relates to a process for preparing the intermediate (R)-(−)lower alkyl nipecotate (+) tartrate salt which involves resolving racemic (±)lower alkyl nipecotate using (+) tartaric acid in an isopropyl alcohol and water mixture. [0019]
  • A further aspect of the claimed invention relates to the purification of the compound of formula I by dissolving the free base of formula I in an organic solvent and adjusting the pH in the range of from about 4 to about 12 in the presence of an organic amine base to precipitate the purified compound of formula I. [0020]
  • Costanzo, et al., in WO97/41102, Nov. 6, 1997 disclose the compound of formula Ia as a free base. A further aspect of the claimed invention relates to a novel crystalline form of the compound of formula Ia. [0021]
    Figure US20020137937A1-20020926-C00009
    • DETAILED DESCRIPTION OF THE INVENTION
  • As used herein, the term “alkyl” whether used alone or as part of a substituent group, include straight and branched chains. For example, alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and the like. Unless otherwise noted, “lower” when used with alkyl means a carbon chain composition of 1-4 carbon atoms. ORT-1593 [0022]
  • As used herein, unless otherwise noted, “aralkyl” shall mean any lower alkyl group substituted with an aryl group such as phenyl, naphthyl and the like. [0023]
  • The term “halogen” means fluorine, chlorine, iodine or bromine. [0024]
  • With reference to substituents, the term “independently” means that when more than one of such substituents is possible, such substituents may be the same or different from each other. [0025]
  • The term “hydrogenation catalyst” shall mean a catalyst of rhodium (Rh), palladium (Pd) or platinum (Pt) which is adsorbed on a solid support such as Rh on carbon, Pd on carbon, Pd(OH) [0026] 2 on carbon or Pt on carbon or unsupported such as PtO2.
  • In a preferred embodiment of the invention, the process relates to a process of preparing a compound of formula I wherein R[0027] 1 and R2 are hydrogen.
  • The invention relates to a process of preparing a compound of formula I as more fully described in the schemes below. [0028]
    Figure US20020137937A1-20020926-C00010
  • As set forth in Scheme 1 above, 3-(4-pyridine)acrylic acid, a known compound, is reduced to 3-(4-piperidyl)propionic acid by catalytic hydrogenation in a basic solvent such as inorganic bases, for example, alcoholates, hydroxide, hydrogen carbonate, carbonate of alkali or earth alkali metals or ammonia; or organic bases, for example, primary, secondary, or tertiary alkylamines, in aqueous or alcoholic solution, preferably aqueous ammonia, in the presence of a rhodium catalyst, preferably rhodium on Al[0029] 2O3 at a temperature of from about room temperature to about 95°, preferably 80-95° C. at a pH in the range of about 7-13, preferably about 7-8.
  • 3-(4-Piperidyl)propionic acid is reacted with a reagent capable of placing a benzyloxy carbonyl protecting group on an amine such as N-(benzyloxy carbonyloxy) succinimide (Cb[0030] zOSu), N-benzyloxy carbonyloxy-5-norbornene-2,3-dicarboximide, or benzyl chloroformate, preferably benzyl chloroformate in a basic calcium salt, such as aqueous Ca(OH) 2 or calcium carbonate, preferably Ca (OH)2, at a temperature in the range of from 0 to room temperature, preferably 0-10° C. and preferably at a pH in the range of about 8-14, preferably about 11-14, to form the 3-(N-benzyloxycarbonyl-4-piperidyl) propionic acid calcium salt of formula II.
  • The salt of formula II is reacted with (R)-(−)lower alkyl nipecotate tartrate of formula III, a known compound or compound prepared by known methods (J. Org. Chem., 1974, 39(7), 893; Eur., J. Pharmacol., 1983, 89(3-4)217), in the presence of a coupling reagent such as 1,3-dicylcohexyl carbodiimide (DCC), O-benzotriazole-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU), or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, preferably DCC, in the presence of 0 to 1 equivalents, preferably 0.1 equivalents, of an additive such as 1-hydroxybenzotriazole hydrate (HOBT) or 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (HOOBT), preferably HOBT, in a solvent mixture of an organic solvent and water, such as, ethyl acetate/water or tetrahydrofuran/water or a polar organic solvent, such as dimethylformamide or 1-methyl-2-pyrrolidinone (NMP), at a temperature in the range of from 0-50° C. preferably 15-25° C. and at a pH in the range of from about 6-10, preferably about 6-7, to form the corresponding compound of formula IV. [0031]
  • The compound of formula IV is hydrolyzed in an inorganic base such as lithium hydroxide, sodium hydroxide, preferably lithium hydroxide, in an organic solvent such as THF or dioxane, at a temperature in the range of from about 0 to about 50° C., preferably 5-25° C. at a pH preferably in the range of about 10 to about 13, to form the compound of formula V. [0032]
  • The compound of formula V is reacted with a carboxylic acid salt of the compound of formula VI, preferably the tartrate salt, in the presence of a coupling reagent such as 1,3-dicyclohexylcarbodiimide (DCC), 0-benzotriazole-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU), or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, preferably DCC, in the presence of 0 to 1 equivalents, preferably 0.1 equivalents of an additive such as 1-hydroxybenzotriazole hydrate (HOBT) or 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (HOOBT), preferably HOBT, preferably DCC and HOBT, in the presence of a calcium salt such as calcium hydroxide, calcium carbonate, and the like, preferably calcium hydroxide, in an amount of at least 1 equivalent, to form the corresponding compound of formula VII, in a solvent mixture of an organic solvent and water, such as, ethyl acetate/water or tetrahydrofuran/water or a polar organic solvent, such as dimethylformamide or 1-methyl-2-pyrrolidinone (NMP) at a temperature in the range of from 0-50° C. preferably 15-25° C. and at a pH in the range of from about 6-10, preferably about 6-7. [0033]
  • Alternatively, the compound of formula V is reacted with a compound of formula VI or an inorganic salt thereof, preferably HCl salt, a known compound or compound prepared by known methods WO 97/41102, in the presence of a coupling reagent such as 1,3-dicyclohexylcarbodiimide (DCC), 0-benzotriazole-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU), or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, preferably DCC, in the presence of 0 to 1 equivalents, preferably 0.1 equivalents of an additive such as 1-hydroxybenzotriazole hydrate (HOBT) or 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (HOOBT), preferably HOBT, preferably DCC and HOBT, to form the corresponding compound of formula VII, in a polar organic solvent such as acetonitrile, DMF, NMP, preferably acetonitrile, in the presence of an organic base such as triethylamine, diisopropylethylamine (DIPEA) or 4-methyl morpholine (NMM), preferably NMM, at a temperature in the range of 0-35° C., and at a pH in the range of about 7-11, preferably in the range of about 8-10. [0034]
  • The compound of formula VII is reacted in an organic solvent, such as THF, dioxane, or DMF, preferably THF, in the presence of an inorganic base such as sodium hydroxide, or lithium hydroxide, preferably lithium hydroxide, at a temperature in the range of from 0-40° C., preferably 10-15° C., preferably at a pH in the range of about 8-11. The resulting mixture is acidified with an inorganic acid such as sulfuric, hydrochloric, and the like, preferably to a pH of about 3-5, to yield the corresponding compound of formula VIII. When the mixture is acidified with sulfuric acid, the acidification results in the precipitation of N,N′-bis(2,2,2-trichloro-1-hydroxyethyl)urea (DCU), which is preferably removed prior to the next step. [0035]
  • The compound of formula VIII is converted to the corresponding compound of formula I via catalytic hydrogenation using a hydrogenation catalyst, preferably a palladium catalyst such as Pd/C, in a polar solvent such as an alcohol, preferably methanol or ethanol, at a temperature of from 30-50° C. [0036]
  • The compound of formula I is purified by heating the compound of formula I in an organic solvent such as ethylacetate, methyl t-butyl ether, methanol, ethanol, n-butanol and the like, preferably n-butanol, to a temperature up to 85°, preferably 75-85° C. The solution is then cooled to a temperature in the range of about 20-30° C. An amine organic base such as triethylamine, cyclohexylamine, t-butylamine and the like, preferably t-butylamine, is added in an amount sufficient to result in a pH in the range of about 4-12, preferably about 7-11, most preferably 7.5. [0037]
    Figure US20020137937A1-20020926-C00011
  • As set forth in Scheme 2 above, a compound of formula IX, a known compound or compound prepared by known methods, J. Am. Chem Soc 1957, Vol. 79, p. 159, is converted to a corresponding compound of formula X by dissolution in an organic solvent such as, methanol, isopropanol, toluene and mixtures thereof, with at least one equivalent of gaseous NH[0038] 3 at a temperature in the range of from 40-100° C., preferably 60-65° C. in the presence of a carboxylic acid such as acetic acid or formic acid.
  • The compound of formula X is reduced to the corresponding compound of formula XI, preferably by reacting with borohydride reagents such as sodium borohydride, in an organic solvent such as THF, in the presence of an organic acid such as propionic acid, benzoic acid, acetic acid, or trifluoroacetic acid (TFA), preferably acetic acid or TFA, at a temperature in the range of −5 to 10° C. at a pH in the range of about 1-6. [0039]
  • In the case where the compound of formula X is reduced by reacting with a borohydride reagent, the reaction is quenched with an alcohol, preferably methanol and a strong acid such as hydrochloric or sulfuric, preferably hydrochloric, to afford a compound of formula XI as a salt. The amine is freed by reacting the salt of the compound of formula XI with a tertiary amine such as triethylamine, DIPEA, or NMM, preferably triethylamine, in an organic solvent such as acetonitrile, THF, or dioxane, preferably acetonitrile. The resulting tertiary amine salt is separated by conventional methods such as filtration or extraction, preferably filtration, to afford the compound of formula XI as the free amino ester. [0040]
  • The compound of formula XI is heated in the presence of (+)-tartaric acid, preferably 0.25 equivalents of (+) tartaric acid, to a temperature resulting in the formation of a solution in a polar solvent, such as alcohol, for example, methanol or ethanol or an alcohol water mixture, such as methyl alcohol/water or ethyl alcohol/water, preferably ethyl alcohol/water mixture at a ratio of 90:10 to 100% ethanol, preferably at a ratio of 97:3 and cooled to a temperature in the range of 25-30° C. to form the corresponding salt of formula XII. [0041]
  • The tartrate salt of formula XII is converted to the corresponding compound of formula VI or salt thereof, by known methods. Preferably, the salt of formula XII is reacted with at least two equivalents, preferably between 8 and 11 equivalents, of gaseous HCl, in a polar solvent, such as methanol, ethanol, isopropyl alcohol, ethyl acetate or mixture thereof, at a temperature in the range of 0-50° C., preferably at about 10° C., to form the corresponding dihydrochloride salt of formula VI. When R[0042] 4 is methyl, the preferred solvent is methanol.
    Figure US20020137937A1-20020926-C00012
  • As set forth in Scheme 3 above, the compound of formula XIII, a known compound or compound prepared by known methods (Eur. J. Pharmacol., 1983, 89(3-4),217), is reacted with (+)tartaric acid, preferably one equivalent (+) tartaric acid in a mixture of isopropyl alcohol (IPA) and water, preferably at a ratio of 90:10 up to 100% IPA, more preferably at a ratio of 94:6, and heating to form a solution, preferably at a temperature in the range of from 73-77° C. then cooled to no less than 20° C., preferably 26-30° C., to form the corresponding salt of formula III. [0043]
  • A further aspect of the present invention is a novel crystalline forms of the compound of formula Ia, characterized by its x-ray powder diffraction pattern, utilizing a Philips PW3710 based powder diffractometer using CuK[0044] α radiation and the following system conditions:
  • a) CuKα radiation, 30 mA, 50 KV [0045]
  • b) Optics [0046]
  • {fraction (1/12)}° divergence slit [0047]
  • 0.2 receiving slit [0048]
  • c) Scan 5.01 to 34.97° 2° at a scan rate of [0049]
  • 0.020°/1.25 sec 2θ/second [0050]
  • d) Aluminum sample holder [0051]
  • The novel crystal form of the compound of formula Ia appears as irregular acicular particles crystals and may be characterized essentially by its X-ray diffraction pattern: [0052]
    POWDER X-RAY DIFFRACTION RESULTS
    d Spacing Relative
    Angle ° 2θ (Å) Intensity (%)
     8.77 10.09  17.50
    10.52 8.41 16.20
    15.57 5.69 100.00 
    15.90 5.65 22.70
    16.52 5.37 48.30
    17.48 5.08 25.80
    17.72 5.01 24.70
    18.32 4.85 58.10
    19.62 4.53 21.50
    19.98 4.45 47.30
    20.28 4.38 41.50
    21.08 4.22 67.80
    21.36 4.16 18.10
    22.82 3.90 23.50
    23.26 3.83 50.40
    24.01 3.71 57.60
    24.73 3.60 24.10
    25.62 3.48  9.90
    25.99 3.43  8.00
    26.37 3.38  4.60
    27.37 3.26 13.50
    27.98 3.19 23.20
    28.62 3.12 15.70
    30.20 2.96 19.00
    30.71 3.41 17.30
    31.29 2.86 32.40
    31.40 2.85 33.30
    31.73 2.82 25.10
    32.71 2.74 12.40
    33.84 2.65  9.70
    34.55 2.60 10.20
  • The following examples describe the invention in greater detail and are intended to illustrate the invention, but not to limit it.[0053]
    • EXAMPLE 1 3-(4-Piperidyl)propionic Acid
  • 3-(4-pyridine)acrylic acid (18 kg) was added to 75 kg of water. The resulting suspension was stirred and neutralized (pH 7.5) with 6.8 kg of aqueous ammonia (25%). A slurry of Rh/Al[0054] 2O3 (0.9 kg) in 5 kg of water was added to the reaction mixture, which was then made inert under nitrogen. The mixture was hydrogenated under a pressure of 3-3.5 bar at 85-95° C. After eight hours, when no further change in pressure was observed, the mixture was cooled to 25-35° C. The catalyst was filtered and washed 20 with 4.0 kg of water. Ammonia and most of the water in the reaction mixture were removed under vacuum at 80-90° C., and the product began to precipitate. Acetonitrile (116 kg) was added and then the mixture was concentrated (ca. 50%) under vacuum. Additional acetonitrile (57.1 kg) was added to aid in crystallization and the reaction mixture was stirred for 1-4 hours at 15-25° C. until precipitation of the product was complete. The product was centrifuged and oven dried under vacuum at 45-55° C. to afford 19.1 kg (100%) of the title compound.
    • EXAMPLE 2 Di 3-(N-Benzyloxycarbonyl-4-piperidyl)propionic Acid Calcium Salt
  • 3-(4-Piperidyl)propionic acid (20.0 g, 0.12 mol) and calcium hydroxide (14.1 g, 0.19 mol) were suspended in 47 g water and 195 g acetonitrile at 15-25° C. and then cooled to 0-10° C. Benzyl chloroformate (23.9 g, 0.14 mol) was added within 30 minutes and the reaction stirred at 0-5° C. for 2 h. The product precipitated during the reaction and was isolated by filtration to afford the title compound in 95% yield. [0055]
    • EXAMPLE 3 (R)-(−)-Ethyl Nipecotate Tartrate
  • L-(+)-Tartaric acid (47.74 g, 318 mmol) was suspended in 265 g of isopropyl alcohol and 16.91 g of water. The mixture was heated to 60-65° C. to afford a homogeneous solution. One equivalent of (±)-ethyl nipecotate (50 g, 318 mmol) was added while the temperature was maintained at or below 75° C. The mixture was stirred at 70-75° C. for 20-30 minutes, then cooled to 60° C. over 60 minutes. Seed crystals of (R)-(−)-ethyl nipecotate -L-(+)-tartrate (25 mg, 0.08 mmol) were added and the reaction was cooled to 26-30° C. over three hours. The temperature was maintained at 26-30° C. for 30 minutes until precipitation was complete. The product was isolated (62.0 g, 94.8% de) and washed twice with a mixture of isopropyl alcohol (21.05 g) and water (1.34 g). The crude product was slurried in a mixture of isopropyl alcohol (188 g) and water (12 g) at 73-77° C. After stirring for 10-20 minutes, the suspension was cooled to 26-30° C. Temperatures exceeding 30° C. will result in less yield, while a temperature of less than 25° C. resulted in de <98%. The product was isolated by filtration and washed twice with a mixture of isopropyl alcohol (21.05 g) and water (1.34 g). This afforded the title compound as a white powder in 72% yield, 98.8% de. [0056]
    • EXAMPLE 4 (R)-1-[3-(1-benzyloxycarbonyl-4-piperidyl)-propionyl]-3-piperidinecarboxylic Acid
  • 3-(N-Benzyloxycarbonyl-4-piperidyl)propionic acid calcium salt (21.9 g, 32.2 mmol), (R)-ethyl nipecotate (21.7 g, 70.8 mmol), and hydroxy benzyltriazole (HOBT) (1.30 g, 9.65 mmol) were suspended in water (40 g) and THF (80 g). The resulting suspension was adjusted to pH 7 with Ca(OH)[0057] 2. Ca-tartrate precipitated and was collected by filtration and washed with 10 g THF. To the filtrate was added slowly a solution of DCC (19.9 g, 96.5 mmol) in 40 g of THF at 0-5° C. The reaction mixture was warmed slowly to 20-25° C. and N,N-dichlorourethane (DCU) precipitated. After 4h, the DCU was removed by filtration and washed with 8 g of THF. The filtrate was cooled to 0-5° C. and lithium hydroxide (6.67 g, 159.0 mmol) in 60.38 g of water was added at 0-5° C. The pale yellow solution was warmed to ambient temperature. After 3 h, the solvent was removed by distillation under vacuum at or below 55° C. Ethyl acetate (45.4 g) was added and the pH was adjusted to exactly 4.0 with ca. 18.6 g of concentrated HCl. DCU precipitated and was filtered from the mixture. The layers were separated and the aqueous layer was washed twice with 31.8 g of ethyl acetate. The combined organic layers were washed twice with a solution of 15.8 g NaCl in 47.2 g of water. The ethyl acetate layer was separated and the solvent was removed by distillation under vacuum at or below 55° C. The product remained as a thick pulp. MTBE (70.8 g) was added and the suspension was stirred for 30 minutes at 45-50° C., then cooled to 15-25° C. and stirred for one hour until crystallization was complete. The product was centrifuged and washed with 6.3 g of MTBE, then dried under vacuum at 40-50° C. to afford the title compound in 92% yield and >98% ee.
    • EXAMPLE 5 Methyl (S)-3-Amino-3-(3-pyridylypropanoate Dihydrochloride
  • Two separate procedures were developed to synthesize this compound. The first procedure (A) involved two steps for the production of enantiomerically pure methyl(s)-3-amino-3-(3-pyridyl)propanoate dihydrochloride via NaBH[0058] 4 reduction. The second procedure (B) involved three steps for the production of enantiomerically pure methyl(S)-3-amino-3-(3-pyridyl)propanoate dihydrochloride via hydrogenation.
  • Procedure A: [0059]
  • Methyl 3-Amino-3-(3-pyridyl)-2-propenoate [0060]
  • A suspension of methyl nicotinoylacetate dihydrochloride (50.0 g, 0.23 mol, dried) and sodium acetate (19.0 g, 0.23 mol) in glacial acetic acid (1.4 g, 0.02 mol), toluene (50 g), and methanol (50 g) was heated to 60-65° C. Ammonia (14.0 g, 0.82 mol) was bubbled through the suspension. After four hours, no starting material was present by HPLC. Two-thirds of the solvents were removed by distillation. The solution was stirred at 0° C. for one hour, and the precipitate was collected by filtration and dried to yield 83% of methyl 3-amino-3-(3-pyridyl)-2-propenoate. The crude product was used as is without further purification. [0061]
  • Methyl 3-Amino-3-(3-pyridyl)propanoate Dihydrochloride [0062]
  • Glacial acetic acid (526.9 g, 8.78 mol) was added dropwise at ←5° C. to a suspension of methyl 3-amino-3-(3-pyridyl)-2-propenoate (0.45mol) and sodium borohydride (44.3 g, 1.17mol) in THF (500 g) and the resulting reaction mixture was stirred at −5-0° C. After 5 h, methanol (600 9) was added dropwise to the solution at -5-0° C. After 0.5 hours, HCl (163 g, 4.47 mol) was bubbled through the solution and stirred at 0° C. After 8 h, the white precipitate was filtered off and dried at 40° C. to yield 101.6 g (89%) of methyl 3-Amino-3-(3-pyridyl)propanoate dihydrochloride. [0063]
  • Procedure B: [0064]
  • Methyl 3-Amino-3-(3-pyridyl)-2-propenoate [0065]
  • Methyl nicotinoylacetate (88 g, 0.5 mol) was dissolved in toluene (200 g), isopropyl alcohol (200 g), and formic acid (98-100%, 1.22 g, 0.03 mol) and heated to 60-65° C. Gaseous ammonia (23 g, 1.35 mol) was bubbled through the solution for 15 minutes. The white suspension was stirred at 65° C. until a homogeneous solution formed. The solution was stirred for two hours at 65° C. and then concentrated (ca. 200 g) at 65° C. The residue was cooled to −5° C. with stirring and methyl 3-amino-3-(3-pyridyl)-2-propenoate crystallized as colorless needles. The process of reducing the volume to 50% followed by cooling was repeated three times with the mother liquors. Filtration, washing with toluene, and drying at 30° C. resulted in 77.74 g (88.8%) of methyl 3-amino-3-(3-pyridyl)-2-propenoate as colorless crystals. [0066]
  • Methyl 3-Amino-3-(3-pyridyl)propanoate Dihydrochloride [0067]
  • Dry palladium on charcoal (0.54 g, manufactured by Degussa, 5% Pd/C) was added to a solution of methyl 3-Amino-3-(3-pyridyl)-2-propenoate (5.4 g, 30 mmol) in dry acetic acid (13 g) in a 450 ml Pyrex high-pressure bottle. The reaction mixture was hydrogenated at 3-3.2 bar. After 1.5-2 h, the catalyst was filtered and washed with 20 g of isopropyl alcohol until the wash solvent was no longer yellow. Gaseous HCl (10.6 g, 0.3 mol) was bubbled through the stirred filtrate at 5-15° C. The suspension was cooled to 0-5° C. and stirred for two hours. The resulting white precipitate was filtered, washed with 5 g of isopropyl alcohol, and dried at 45° C. to yield 5.95 g (78.4%,) of methyl 3-Amino-3-(3-pyridyl)propanoate dihydrochloride. [0068]
    • EXAMPLE 6 Methyl (S)-3-amino-3-(3-pyridyl)propanoate Dihydrochloride
  • Racemic methyl 3-amino-3-(3-pyridyl)propanoate dihydrochloride(150 g, 0.563 mol) was suspended in acetonitrile (425 g). Triethylamine (125.3 g, 1.239 mol) was added dropwise while the temperature was maintained at 35° C. or less. The reaction was stirred for a minimum of two hours at 20° C. then cooled to 50C. After 0.5 hours the resulting precipitate was centrifuged and washed with 50 g of acetonitrile. The acetonitrile was removed by distillation at 40-45° C. to afford crude free base of methyl 3-amino-3-(3-pyridyl)propanoate dihydrochloride. The free base (ca. 105 g) was dissolved in 80 g of ethanol. A solution of (+)-tartaric acid (21.1 g, 0.141 mol) in 80 g of ethanol and 5 g of water was added. The reaction mixture was stirred for 4 hours at 20-23° C. The suspension was cooled slowly to 10-15° C., then stirred for an additional two hours. The precipitate was filtered off and washed with 30 g of ethanol. [0069]
  • The crude tartrate salt was slurried at 35-40° C. for two hours in a mixture of 150 g of ethanol and 4.6 g of water. The mixture was stirred for 0.5 hours at 25° C. The resulting precipitate was isolated and washed with 30 g of ethanol. Up to three slurries may be necessary to achieve a >98% de. The precipitate was suspended in methanol (100 g) and a minimum of 10 equiv. HCl gas (51.3 g, 1.408 mol) was added. The reaction mixture was stirred at 22-28° C. until the reaction was complete by HPLC. Ethyl acetate (160 g) was added and the reaction mixture was stirred at 0-5° C. for three hours. The precipitate was filtered and washed with 30 g of cold (0-5° C.) methanol. The product was dried under vacuum at 35-45° C. to yield 39.46 g of the title compound as a white solid (28%, 55% of the desired S-enantiomer). [0070]
    • EXAMPLE 7 [S-(R*,S*)]-β-[[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine Propanoic Acid
  • (R)-1-[3-(1-benzyloxycarbonyl-4-piperidyl)-propionyl]-3-piperidinecarboxylic acid (60 kg, 149 mol) and HOBT (1.98 kg, 14.8 mol) were suspended in acetonitrile (164 kg) at 0-5° C. NMM (33.2 kg, 328.5 mol) and methyl (S)-3-amino-3-(3-pyridyl)propanoate dihydrochloride (39.2 kg, 154.9 mol) were added to the reaction mixture. After 1 h, a solution of DCC (37.2 kg, 180.3 mol) in acetonitrile (117 kg) was added at 0-5° C. The mixture was warmed to 20-25° C. and stirred for 12 hours. The suspension was cooled to 0-5° C. and the precipitated DCU was filtered off and washed with 81 kg of pre-cooled ethyl acetate. The solvent was distilled from the filtrate, and the residual oil was dissolved twice in 50 kg of ethyl acetate and the solvent removed. The resulting oil was dissolved in 162 kg of ethyl acetate and washed three times with a solution of 6.3 kg of NaHCO[0071] 3 in 120 kg of water to remove excess HOBT. The solvent was removed from the organic layer and the resulting oil and/or foam was dissolved twice in 50 kg of THF and evaporated to dryness to afford methyl [S-(R*,S*)-P-[[[1-[1-oxo-3-(1-benzyloxycarbonyl-4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine propanoate as an oil.
  • Crude methyl [S-(R*,S*)-β-[[[1-[1-oxo-3-(1-benzyloxycarbonyl-4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine propanoate was dissolved in 163 kg of THF at 45° C. The clear solution was cooled to 0-5° C. and within 30 to 60 minutes a solution of lithium hydroxide monohydrate (14.3 kg, 340.8 mol) in 151 kg of water was added to the reaction mixture. The pale yellow solution was stirred for 2 h at 20-25° C. HCl (36-38%, 38 kg) was added to achieve a pH of 4.1. NaCl (7.2 kg) was added and the layers were separated. The organic layer was washed twice with a solution of 36.4 kg of NaCl in 72.6 kg of water. The organic layers were distilled and the resulting oil was dissolved in 75 kg of THF. The solvent was removed until a water content of <2% was achieved. The precipitated inorganic salts were removed and washed with 9 kg of THF. The filtrate was evaporated under vacuum at 45° C. to afford [S-(R*,S*)-β-[[[1-[1-oxo-3-(1-benzyloxycarbonyl-4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine propanoic acid as an oil. [0072]
  • Crude [S-(R*,S*)-β-[[[1-[1-oxo-3-(1-benzyloxycarbonyl-4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine propanoic acid was dissolved in 312 kg of methanol. A suspension of 60 kg of methanol and 15 kg of slurried Pd/C (wet) was added to the reaction mixture, which was then hydrogenated under pressure (2-3 bar) with stirring at 38-42° C. When the hydrogenation was finished, the catalyst was filtered through Hyflo SuperCel and washed with 39 kg of methanol. The filtrate was reduced to a colorless oil under reduced pressure at 40-50° C. The crude product was dissolved in 60 kg of n-butyl alcohol and concentrated to an oil, which began to bubble or foam. The crude product was slurried in 756 kg of n-butyl alcohol and heated to 75-85° C. for 15-20 minutes, then cooled to 20-30° C. t-Butylamine (0.7 kg) was added (pH 7.5) and the reaction was stirred. The reaction mixture was cooled to 0-5° C. and stirred for an additional hour. The precipitate was isolated, washed with 102 kg of MTBE, and dried under vacuum at 60-80° C. to yield 36 kg (58%) of the title compound as a white crystalline solid. [0073]
    • EXAMPLE 8 [S-(R*,S*)]-β-[[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine Propanoic Acid
  • (R)-1-[3-(1-benzyloxycarbonyl-4-piperidyl)-propionyl]-3-piperidinecarboxylic acid (1 kg, 2.48 mol), methyl (S)-3-amino-3-(3-pyridyl)propanoate tartrate (where the tartrate is present as a hemi-tartrate) (0.7 kg, 2.73 mol) and HOBT (38 g, 0.25 mol) were added to a reaction vessel. To the mixture was added a previously prepared cold solution (0-5° C.) of KH[0074] 2PO4 (96.8 g, 0.71 mol) and Na2HPO4 (69.2 g, 0.49 mol) in water (3 kg) and THF (2 kg) The pH was then adjusted to 6.0-6.4 using calcium hydroxide (110 g). The resulting suspension was cooled to 0-5° C. and a solution of DCC (564 g, 2.73 mol) in THF (1 kg) was added. The mixture was stirred for lh at 0-5° C., warmed to 20-25° C. and stirred for 4 h. The suspension was cooled to 0-5° C. and ethyl acetate (2 kg) was added. After 15 minutes, the precipitate (a mixture of DCU and calcium tartrate) was filtered off and washed with pre-cooled THF (1 kg). The phases were separated and the organic phase was washed with 5% NaHCO3 (1 kg). The organic phase was concentrated at 40-50° C., the residual oil was dissolved in THF (1 kg) and evaporated to dryness to afford methyl [S-(R*,S*)-β-[[[1-[1-oxo-3-(1-benzyloxycarbonyl-4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine propanoate as an oil.
  • Crude methyl [S-(R*,S*)-β-[[[1-[1-oxo-3-(1-benzyloxycarbonyl-4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine propanoate was dissolved in THF (1.4 kg) at 45° C. The clear solution was cooled to 0-5° C. Within 30-90 min, a solution of lithium hydroxide monohydrate (182 g, 4.21 mol) in water (1.9 kg), cooled to 5° C., was added to the reaction mixture. The solution was stirred for 0.5 h at 0-5° C., warmed to 20-25° C. and stirred for an additional 1 h. The reaction mixture was cooled to 0-5° C. and treated with a solution of sulfuric acid (250 g) in water (1.14 kg) to achieve a pH of 3.9-4.1. The precipitated DCU was collected by filtration and washed with THF (400 g). The resulting phases were separated and the organic phase washed with a saturated NaCl solution (1 kg). The organic layer was distilled and the resulting oil dissolved in THF (2 kg). The solvent was removed until a water content of <2% was achieved. The precipitated inorganic salts were removed. The filtrate was concentrated and the resulting oil dissolved in MeOH (2kg). The solution was evaporated under vacuum at 45° C. to afford [S-(R*,S*)-β-[[[1-[1-oxo-3-(1-benzyloxycarbonyl-4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine propanoic acid as an oil. [0075]
  • Crude [S-(R*,S*)-β-[[[1-[1-oxo-3-(1-benzyloxycarbonyl-4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridine propanoic acid was dissolved in a suspension of Pd/C (261 g) in MeOH (3 kg). The reaction mixture was hydrogenated under pressure (2-3 bar) with stirring at 30-40° C. After 6 h, the catalyst was filtered through Hyflo SuperCel and washed with methanol (1.04 kg). The filtrate was concentrated under reduced pressure at 40-50° C. The crude product was dissolved in n-butyl alcohol (1 kg) and concentrated to an oil. The crude product was taken up in n-butyl alcohol (1.7 kg) and heated to 75-85° C. for 1-3 h, then cooled to 20-30° C. for 2-3 h. The resulting suspension was cooled to 0-5° C. and stirred for an additional 1 h. The precipitate was isolated, washed with MTBE (1.7 kg), and dried under vacuum at 60-80° C. to yield 36 kg (53%) of the title compound as a white crystalline solid. [0076]

Claims (19)

1. A process for preparing a compound of formula I
Figure US20020137937A1-20020926-C00013
wherein R1 and R2 are independently selected from the group consisting of hydrogen, lower alkyl and halogen, comprising reacting the salt of formula II
Figure US20020137937A1-20020926-C00014
with the salt of formula III
Figure US20020137937A1-20020926-C00015
at a pH in the range of about 6 to 10 to form the compound of formula IV
Figure US20020137937A1-20020926-C00016
reacting the compound of formula IV to form the compound of formula V
Figure US20020137937A1-20020926-C00017
reacting the compound of formula V with a compound of formula VI
Figure US20020137937A1-20020926-C00018
at a pH in the range of about 7 to 11 to form the compound of formula VII
Figure US20020137937A1-20020926-C00019
reacting the compound of formula VII to form the compound of formula VIII
Figure US20020137937A1-20020926-C00020
and reacting the compound of formula VIII with hydrogen in the presence of a hydrogenation catalyst to form the compound of formula I.
2. The process of claim 1, wherein in the compound of formula I R1 and R2 are hydrogen.
3. A process for preparing a compound of formula VI
Figure US20020137937A1-20020926-C00021
wherein R1 and R2 are independently selected from hydrogen, lower alkyl and halogen, and R4 is lower alkyl or aralkyl, or salt thereof comprising reacting a compound of formula XI
Figure US20020137937A1-20020926-C00022
with (+)tartaric acid to form the salt of formula XII
Figure US20020137937A1-20020926-C00023
and reacting the salt of formula XII to form the compound of formula VI or salt thereof.
4. The process of claim 3, wherein in the compound of formula XI R4 is methyl and the (+)tartaric acid is present in an amount of 0.25 equivalents.
5. The process of claim 4, wherein in the compound of formula VI, R1 and R2 are hydrogen and R4 is methyl.
6. The process of claim 4, wherein the salt of formula XII is reacted with gaseous HCl in methanol to form the dihydrochloride salt of formula VI.
7. A process of preparing a salt of formula III
Figure US20020137937A1-20020926-C00024
wherein R3 is lower alkyl comprising reacting a compound of formula XIII
Figure US20020137937A1-20020926-C00025
with (+)tartaric acid in a mixture of isopropyl alcohol and water.
8. The process of claim 7, wherein in the salt of formula III, R3 is ethyl.
9. The process of claim 8, wherein in the mixture of isopropyl alcohol and water the isopropyl alcohol is present in a ratio of from 90 percent isopropyl alcohol to 10 percent water to 100 percent isopropyl alcohol.
10. A process of purifying a compound of formula I
Figure US20020137937A1-20020926-C00026
wherein R1 and R2 are independently selected from the group consisting of hydrogen, lower alkyl and halogen, comprising reacting the free base of formula I at a pH in the range of from about 4 to 12 in the presence of an organic amine base.
11. The process of claim 10, wherein in the compound of formula I R1 and R2 are hydrogen.
12. The process of claim 11, wherein the organic amine base is triethylamine, cyclohexylamine, or t-butylamine and the reaction is carried out at a pH in the range of from about 7 to 11.
13. The process of claim 12, wherein the reaction is carried out at a pH of 7.5.
14. The process of claim 13, wherein the organic amine base is t-butylamine.
15. A process for preparing a compound of formula VIII
Figure US20020137937A1-20020926-C00027
wherein R1 and R2 are independently selected from the group consisting of hydrogen, lower alkyl and halogen, comprising reacting a compound of formula V
Figure US20020137937A1-20020926-C00028
wherein Ph is phenyl,
with a carboxylic acid salt of a compound of formula VI
Figure US20020137937A1-20020926-C00029
wherein R1 and R2 are independently selected from the group consisting of hydrogen, lower alkyl and halogen, and R4 is lower alkyl or aralkyl,
in the presence of a calcium salt, in an amount equal to at least 1 equivalents, at a pH in the range of about 6-10.
16. The process of claim 15, wherein the carboxylic acid salt of the compound of formula VI is tartrate salt.
17. The process of claim 15, wherein the calcium salt is calcium hydroxide.
18. The process of claim 15, wherein the pH is in the range of about 6-7.
19. A crystalline form of the compound of formula Ia
Figure US20020137937A1-20020926-C00030
characterized essentially by the following X-ray diffraction pattern:
d Spacing Relative Angle ° 2θ (Å) Intensity (%)  8.77 10.09  17.50 10.52 8.41 16.20 15.57 5.69 100.00  15.90 5.65 22.70 16.52 5.37 48.30 17.48 5.08 25.80 17.72 5.01 24.70 18.32 4.85 58.10 19.62 4.53 21.50 19.98 4.45 47.30 20.28 4.38 41.50 21.08 4.22 67.80 21.36 4.16 18.10 22.82 3.90 23.50 23.26 3.83 50.40 24.01 3.71 57.60 24.73 3.60 24.10 25.62 3.48  9.90 25.99 3.43  8.00 26.37 3.38  4.60 27.37 3.26 13.50 27.98 3.19 23.20 28.62 3.12 15.70 30.20 2.96 19.00 30.71 3.41 17.30 31.29 2.86 32.40 31.40 2.85 33.30 31.73 2.82 25.10 32.71 2.74 12.40 33.84 2.65  9.70 34.55 2.60 10.20
US10/081,289 1999-03-22 2002-02-22 Process for preparing [S- (R*, S*) ] -beta- [ [ [1- [1-oxo-3- (4-piperidinyl) propyl] -3-piperidinyl] carbonyl]amino] -3-pyridinepropanoic acid and derivatives Abandoned US20020137937A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/081,289 US20020137937A1 (en) 1999-03-22 2002-02-22 Process for preparing [S- (R*, S*) ] -beta- [ [ [1- [1-oxo-3- (4-piperidinyl) propyl] -3-piperidinyl] carbonyl]amino] -3-pyridinepropanoic acid and derivatives

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12567199P 1999-03-22 1999-03-22
US09/532,375 US6515130B1 (en) 1999-03-22 2000-03-21 Process for preparing [S-(R*,S*)]-β-[[[1-[1-oxo-3(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridinepropanoic acid and derivatives
US10/081,289 US20020137937A1 (en) 1999-03-22 2002-02-22 Process for preparing [S- (R*, S*) ] -beta- [ [ [1- [1-oxo-3- (4-piperidinyl) propyl] -3-piperidinyl] carbonyl]amino] -3-pyridinepropanoic acid and derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/532,375 Continuation US6515130B1 (en) 1999-03-22 2000-03-21 Process for preparing [S-(R*,S*)]-β-[[[1-[1-oxo-3(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridinepropanoic acid and derivatives

Publications (1)

Publication Number Publication Date
US20020137937A1 true US20020137937A1 (en) 2002-09-26

Family

ID=22420863

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/532,375 Expired - Lifetime US6515130B1 (en) 1999-03-22 2000-03-21 Process for preparing [S-(R*,S*)]-β-[[[1-[1-oxo-3(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridinepropanoic acid and derivatives
US10/081,289 Abandoned US20020137937A1 (en) 1999-03-22 2002-02-22 Process for preparing [S- (R*, S*) ] -beta- [ [ [1- [1-oxo-3- (4-piperidinyl) propyl] -3-piperidinyl] carbonyl]amino] -3-pyridinepropanoic acid and derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/532,375 Expired - Lifetime US6515130B1 (en) 1999-03-22 2000-03-21 Process for preparing [S-(R*,S*)]-β-[[[1-[1-oxo-3(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridinepropanoic acid and derivatives

Country Status (22)

Country Link
US (2) US6515130B1 (en)
EP (1) EP1165543B1 (en)
JP (1) JP2002540108A (en)
KR (1) KR20020019895A (en)
CN (1) CN1351600A (en)
AT (1) ATE242235T1 (en)
AU (1) AU775413B2 (en)
BR (1) BR0010652A (en)
CA (1) CA2368024A1 (en)
CZ (1) CZ20013431A3 (en)
DE (1) DE60003169T2 (en)
DK (1) DK1165543T3 (en)
ES (1) ES2199805T3 (en)
HK (1) HK1046272A1 (en)
HR (1) HRP20010767A2 (en)
HU (1) HUP0201262A3 (en)
MX (1) MXPA01009615A (en)
PT (1) PT1165543E (en)
SK (1) SK13562001A3 (en)
UA (1) UA67832C2 (en)
WO (1) WO2000056730A1 (en)
YU (1) YU74601A (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0201263A3 (en) 1999-03-22 2003-05-28 Ortho Mcneil Pharm Inc Synthesis of 3-amino-3-aryl propanoates and intermediates
JP4570362B2 (en) * 2001-09-21 2010-10-27 サノフィ−アベンティス Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo [1,2-a] pyrimidine-5 (1H) ON derivatives
SG2014011225A (en) 2011-08-17 2014-06-27 Piramal Imaging Sa Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi
CA2900595A1 (en) 2013-02-12 2014-08-21 Bayer Pharma Aktiengesellschaft Metal chelate compounds for binding to the platelet specific glycoprotein iib/iiia
KR102236806B1 (en) 2013-02-20 2021-04-06 로이터 케미쉐 아파라테바우 이.카. Process for the preparation of enantiomerically enriched 3-aminopiperidine
WO2014173855A1 (en) 2013-04-22 2014-10-30 Reuter Chemische Apparatebau Kg Process for preparing enantiomerically enriched 3-hydroxymethylpiperidine
KR102548998B1 (en) 2020-03-31 2023-06-29 재단법인 아산사회복지재단 Radiopharmaceuticals and composition for thrombus imaging

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58243B1 (en) 1983-12-07 1993-08-11 Lonza Ag A process for the preparation of optically-active 3-amino carboxylic acids
US5254573A (en) 1991-10-15 1993-10-19 Monsanto Company Substituted heterocyclic derivatives useful as platelet aggregation inhibitors
ES2164109T3 (en) 1993-09-22 2002-02-16 Fujisawa Pharmaceutical Co DERIVATIVES OF N- (3-PIPERIDINILCARBONIL) -BETA-ALANINA AS PAF ANTAGONISTS.
US5770575A (en) * 1994-03-16 1998-06-23 Ortho Pharmaceutical Corporation Nipecotic acid derivatives as antithrombotic compounds
EP0888302A1 (en) * 1996-03-13 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. N- (r)-1- 3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine as fibrinogen receptor antagonist
CN1286684A (en) * 1996-05-01 2001-03-07 奥索·麦克尼尔药品公司 Carboxamide derivs. of pyrrolidine, piperidine and hexahydroazepine for treatment of thrombosis disorders
ATE209179T1 (en) 1996-07-12 2001-12-15 Searle & Co ASYMMETRIC SYNTHESIS OF CHIRAL BETA-AMINO ACIDS
US6066651A (en) * 1997-10-29 2000-05-23 Ortho-Mcneil Pharmaceutical, Inc. Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders

Also Published As

Publication number Publication date
EP1165543B1 (en) 2003-06-04
HU0201262D0 (en) 2002-05-29
AU3766100A (en) 2000-10-09
HRP20010767A2 (en) 2002-12-31
CZ20013431A3 (en) 2003-04-16
EP1165543A1 (en) 2002-01-02
US6515130B1 (en) 2003-02-04
CN1351600A (en) 2002-05-29
BR0010652A (en) 2002-07-16
DE60003169T2 (en) 2005-10-27
UA67832C2 (en) 2004-07-15
ES2199805T3 (en) 2004-03-01
AU775413B2 (en) 2004-07-29
CA2368024A1 (en) 2000-09-28
SK13562001A3 (en) 2002-08-06
DE60003169D1 (en) 2003-07-10
MXPA01009615A (en) 2003-07-21
YU74601A (en) 2004-05-12
JP2002540108A (en) 2002-11-26
WO2000056730A1 (en) 2000-09-28
HK1046272A1 (en) 2003-01-03
DK1165543T3 (en) 2003-09-29
HUP0201262A3 (en) 2003-12-29
HUP0201262A2 (en) 2002-08-28
PT1165543E (en) 2003-10-31
KR20020019895A (en) 2002-03-13
ATE242235T1 (en) 2003-06-15

Similar Documents

Publication Publication Date Title
CA2209904C (en) Di-substituted 1,4-piperidine esters and amides having 5-ht4 antagonistic activity
US7989494B2 (en) Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
JP5863789B2 (en) Method for producing pyrazole derivative
US6515130B1 (en) Process for preparing [S-(R*,S*)]-β-[[[1-[1-oxo-3(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridinepropanoic acid and derivatives
WO2006040156A1 (en) Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines
CN1255402C (en) Intermediates for the production of quinolone carboxylic acid derivatives
US5476942A (en) 1-[2-amino-5-[1-(triphenylmethyl)-1H-imidazol-4-YL]-1-oxopentyl] piperidine derivatives, their preparation and their use as synthetic intermediates
SG182576A1 (en) Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide
CN119306698B (en) A new method for preparing zavigepan intermediate
JPWO1995000502A1 (en) Novel synthetic intermediates and methods for producing aminopiperazine derivatives
US6150417A (en) Phenoxyethylamine derivatives, method of preparation application as medicine and pharmaceutical compositions containing same
KR100758522B1 (en) Novel benzamide derivatives and process for production thereof
JP3266603B2 (en) Method for producing 3- (7-amidino-2-naphthyl) -2-phenylpropionic acid derivative
WO2012085935A2 (en) Compounds as inhibitors of renin

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION